This page will host Events plug-in for all Clarion and trade events.

Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Savara, Inc. - Common Stock (NQ:SVRA)

5.250 +0.090 (+1.74%)
Streaming Delayed Price Updated: 10:20 AM EDT, Apr 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Savara, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
News headline image
Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference
From Savara Inc.
Via Business Wire
News headline image
Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
From Savara Inc.
Via Business Wire
News headline image
Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
From Savara Inc.
Via Business Wire
News headline image
Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update
From Savara Inc.
Via Business Wire
News headline image
Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
From Savara Inc.
Via Business Wire
News headline image
Savara Announces Participation in 2026 Citizens Life Sciences Conference
From Savara Inc.
Via Business Wire
News headline image
Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
From Savara Inc.
Via Business Wire
News headline image
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
News headline image
Savara Announces Participation in Upcoming Investor Healthcare Conferences
From Savara Inc.
Via Business Wire
News headline image
Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*
From Savara Inc.
Via Business Wire
News headline image
SAVARA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Savara, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
News headline image
PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*
From Savara Inc.
Via Business Wire
News headline image
Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
From Savara Inc.
Via Business Wire
News headline image
Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
From Savara Inc.
Via Business Wire
News headline image
Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*
From Savara Inc.
Via Business Wire
News headline image
Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System
From Savara Inc.
Via Business Wire
News headline image
Savara Announces Participation in Upcoming Investor Healthcare Conferences
From Savara Inc.
Via Business Wire
News headline image
Savara Reports Third Quarter 2025 Financial Results and Provides Business Update
From Savara Inc.
Via Business Wire
News headline image
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Class Action Filed Against Savara Inc. (SVRA) - November 7, 2025 Deadline to Join - Contact Levi & Korsinsky
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Class Action Filed Against Savara Inc. (SVRA) - November 7, 2025 Deadline to Join - Contact Levi &amp; Korsinsky
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Deadline Soon: Savara Inc. (SVRA) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
SAVARA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urgently Reminds Savara Stockholders to Contact the Firm Before November 7th
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Savara
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
November 7, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against SVRA
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
November 7, 2025 Deadline: Contact Levi &amp; Korsinsky to Join Class Action Suit Against SVRA
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Investors Who Lost Money on Savara Inc. (SVRA) Should Contact Levi & Korsinsky About Pending Class Action - SVRA
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.